NCT03478514 2026-04-09
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
Clinical Trials
22 trialsNCT05254743 2026-04-01
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT03229200 2025-10-30
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
Phase 4 Active not recruiting
NCT03424122 2025-08-21
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Incyte Corporation
Phase 1 Completed
NCT04662255 2025-05-28
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT01855750 2025-02-04
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT04234061 2024-11-07
TARMAC
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT02733042 2023-11-18
FUSION NHL 001
Celgene
Phase 1/2 Completed
NCT05431179 2023-04-21
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
Phase 3 Withdrawn
NCT04665115 2022-08-03
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT01109069 2020-05-27
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Phase 2 Completed
NCT01980628 2019-10-16
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02950220 2019-07-30
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01980654 2019-04-16
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02272686 2018-12-05
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02055924 2018-10-11
BIBLOS
The Lymphoma Academic Research Organisation
Phase 1 Terminated
NCT01325701 2017-03-31
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02670317 2017-03-20
FIL-GALILEO
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated
NCT01292135 2014-07-24
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Pharmacyclics LLC.
Phase 1 Completed
NCT01105247 2014-03-31
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Phase 1/2 Completed
NCT00849654 2013-05-22
PCYC-04753
Pharmacyclics LLC.
Phase 1 Completed